XTuit racks up $22 mln in NEA-led round
Cambridge, Massachusetts-based biopharmaceutical company XTuit Pharmaceuticals Inc has secured $22 million in Series A funding. New Enterprise Associates led the round with participation from Polaris Partners, CTI Life Sciences, Arcus Ventures and Omega Funds. In addition to the funding, David Mott, a general partner at New Enterprise Associates, has been appointed to XTuit's board.
11 June 2015•4 mins read
